西亚试剂:AbbVie says to reconsider recommendation for Shire acquisit

发布时间：2025-09-27

AbbVie says to reconsider recommendation for Shire acquisition

Oct 14 (Reuters) - AbbVie Inc said it intends to reconsider its recommendation to its shareholders to vote in favor of the 32 billion pound ($54.7 billion) merger with Shire Plc due to the changing U.S. tax regulations.

Chicago-based AbbVie, which makes top-selling arthritis drug Humira, is eager to buy Shire to reduce its U.S. tax bill by moving its tax base to Britain and to diversifying its drug portfolio.

However, the U.S. Treasury Department unveiled harsher-than-expected changes late last month to its existing rule book for on corporate "inversions," which have become a cause of concern in Washington about the threat posed to the U.S. corporate income tax base.

AbbVie also intends to reduce its reliance on Humira, the world's top selling medicine which loses U.S. patent protection in 2016.

AbbVie's said its board plans to meet on Oct. 20 to consider whether to withdraw or modify its recommendation on the deal with Shire.

"At this time, AbbVie's board of directors has not withdrawn or modified its recommendation to AbbVie stockholders," the company said on Tuesday.

Pfizer Inc tried to similar strategy earlier this year when it made a bid for Britain's AstraZeneca plc worth $118 billion, which was rejected.

Under British takeover rules, AbbVie has until July 18 to announce a firm offer for Shire, extend the deadline for an offer, or walk away.

Dublin-based Shire sells drugs for rare diseases.

• 以上资料由西亚试剂：http://www.xiyashiji.com/ 提供此产品的详细信息如密度,含量,分子式,分子量等均可在西亚官网查询   
• 相关产品如汞乙酸汞氯化汞氧化汞碘化汞硫酸汞硝酸汞溴化汞硝酸亚汞氯化亚汞乙酸苯汞碘化汞钾硫氰酸汞氯化氨基汞三氯生三氯氧磷三氯乙烯水合氯醛三氯化磷三氯化钌三氯化钛三氯化铱三氯化铑三氯硫磷三氯乙烷三氯甲烷三氯卡班TCC1,3,5-三氯苯1,2,4-三氯苯1,2,3-三氯苯无水氯化铝三氯乙酸酐三氯乙酸钠碘甲烷二碘甲烷三碘甲烷 三氟碘甲烷硫酸二甲酯氯磺酸苯硫酚苯硫酚钠3-氨基苯硫酚2,6-二氯苯硫酚2,4-二氯苯硫酚2,5-二氯苯硫酚2-甲氧基苯硫酚2-氯乙醇氯甲基甲醚 等均有销售.欢迎订购

上一篇：西亚试剂：茎干细胞通过CLV3p–FLS2信号触发免疫
下一篇：磷酸二氢钙生产方法